Tobacco Craving and Triggers in Persons With Schizophrenia
NCT01846065 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 45
Last updated 2019-09-25
Summary
Investigators have recently completed a pilot study exploring the safety and efficacy of using a virtual-reality based cue platform to elicit craving in smokers with schizophrenia(SWS)(Wehring et al, unpublished). In this study, participants with schizophrenia (n=16) showed increased attention to cigarettes and changes in craving measures when participating in the VR craving platform. In addition, participants tolerated the VR environment without undue adverse effects or exacerbation of symptoms. Adverse effects from the VR environment did not differ from that in a non-mentally ill population, and included headache, nausea, and dizziness as most commonly occurring factors. Persons in this pilot also showed acceptable rates of Immersion and Presence in the VR environment, showing the potential use of this form of environment for this and other purposes.
In this study, investigators will examine virtual reality cue-reactivity in smokers with schizophrenia, with a focus on the relationship of cue-reactivity with self-identified triggers/cues. Smokers with schizophrenia often identify specific cues that trigger craving. Many of these are environmental (scent, sight of smoking paraphernalia or cigarettes, related objects, or social situations), however, a significant amount of smokers describe emotionally-based factors (sadness, being upset, etc.) as primary cues and triggers. Most methods used to elicit craving in experimental studies are executed via using environmental cues like sight of cigarettes or smoking paraphernalia. It is not known if smokers with schizophrenia(SWS) who are strongly emotionally triggered will be responsive to environmental triggers in a cue-elicited craving platform. This is an important research question, as the testing of anti-craving interventions should be generalizable for use across SWS with differing triggers to smoking. The VR-based environmental program from our pilot study, which includes sight, scent, and social cues, will be used to test pre-identified environmental cues/triggers and their effects on cue-elicited craving in 30 SWS. Subjective reports, mood and emotion measures, and objective physiological measurements will be used to identify and quantify environmental craving responsivity as well as tonic craving.
Given the high prevalence of smoking among individuals with schizophrenia, understanding some of the environmental factors that serve to maintain nicotine dependence is a critical step in improving smoking cessation treatment outcomes. Establishing and validating a model of cue-elicited responsivity will allow future investigations of craving, and ultimately designs for studying the efficacy of anti-craving medications in people with schizophrenia.
Conditions
- Smoker
- Schizophrenia Diagnosis
Sponsors & Collaborators
-
University of Maryland, Baltimore
lead OTHER
Principal Investigators
-
Heidi Wehring, Pharm.D., BCPP · University of Maryland, Baltimore
Eligibility
- Min Age
- 18 Years
- Max Age
- 55 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-09-30
- Primary Completion
- 2016-06-30
- Completion
- 2017-06-30
Countries
- United States
Study Locations
More Related Trials
-
Nicotine and Sensorimotor Replacement for Smoking in Smokers With Schizophrenia
NCT01213524 ·Status: COMPLETED ·Phase: PHASE2
-
The Effects of Nicotine Withdrawal on Reward Responsivity in Schizophrenia
NCT00373126 ·Status: COMPLETED ·Phase: PHASE4
-
Cigarette Smoking in Smokers With and Without Schizophrenia
NCT04001114 ·Status: COMPLETED ·Phase: NA
-
Contingent Incentives Plus Bupropion for Smoking in People With Schizophrenia
NCT00136760 ·Status: COMPLETED ·Phase: PHASE2
-
Minocycline and Tobacco Craving in Smokers With Schizophrenia
NCT02968602 ·Status: COMPLETED ·Phase: PHASE4
-
Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors
NCT00802919 ·Status: COMPLETED ·Phase: PHASE4
-
Influence of Nicotine on Cognitive Function in Schizophrenic Patients With and Without Comorbid Drug Dependence
NCT01037075 ·Status: COMPLETED
-
Brain Circuits in Schizophrenia and Smoking
NCT01369966 ·Status: COMPLETED
-
The Effects of Nicotine on Cognition in Schizophrenia
NCT00383747 ·Status: COMPLETED ·Phase: PHASE4
-
Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates
NCT03495024 ·Status: RECRUITING ·Phase: PHASE4
-
Knowledge and Perception of Smoking Risks/Consequences
NCT00686101 ·Status: COMPLETED
-
Network-Targeted Neuromodulation for Nicotine Dependence in Schizophrenia
NCT06389266 ·Status: COMPLETED ·Phase: NA
-
Examining Persistence in Smokers With Schizophrenia
NCT03346291 ·Status: COMPLETED ·Phase: NA
-
Neural Inhibition as a Mechanism of Nicotine Dependence Among Persons With Schizophrenia
NCT00407277 ·Status: COMPLETED ·Phase: NA
-
Combining rTMS With Varenicline to Prevent Smoking Lapse in Schizophrenia
NCT03497299 ·Status: WITHDRAWN ·Phase: PHASE2
-
Nicotinic Enhancement of Cognitive Remediation Training in Schizophrenia
NCT02069392 ·Status: COMPLETED ·Phase: NA
-
Circuitry-Guided Smoking Cessation in Schizophrenia
NCT03281629 ·Status: COMPLETED ·Phase: NA
-
The Effect of Nicotine on Arousal, Cognition and Social Cognition in Schizophrenic Patients
NCT01186471 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Brain Circuits in Schizophrenia and Smoking
NCT01425684 ·Status: COMPLETED
-
Nicotinic Receptor Density in Smoking and Nonsmoking Schizophrenics
NCT01246128 ·Status: WITHDRAWN
-
Transcranial Direct Current Stimulation (tDCS) As A Treatment For Cigarette Craving and Cognitive Deficits in Schizophrenic
NCT02128919 ·Status: COMPLETED ·Phase: NA
-
Cinematic Virtual Reality Intervention for Improving Psychosocial Functioning in Individuals With Schizophrenia
NCT07326618 ·Status: COMPLETED ·Phase: NA
-
Impact of tDCS on Cannabis Craving in Schizophrenia
NCT05784961 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Investigation of the Effects of Virtual Reality Applications on Individuals Diagnosed With Schizophrenia
NCT07027085 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Varenicline Adjunctive Treatment in Schizophrenia
NCT00492349 ·Status: COMPLETED ·Phase: PHASE4